Chief Mission Officer · GoodRx Holdings, Inc. (GDRX)

Douglas Hirsch

A named executive officer of GoodRx in every fiscal year CompBrief holds from FY2019 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$784,856

Salary $500,000Stock awards $0

FY2022: $507,290

6th of 6 named executive officers at GoodRx by FY2023 total.

6 named officers on file for GoodRx, FY2023

Douglas Hirsch’s pay file — $29

  • 5 fiscal years of pay, line by line
  • GDRX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how GoodRx’s whole pay program stands against its peers

  • GoodRx’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on GDRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 25, 2024 (DEF 14A).

Free

Get Douglas Hirsch’s full pay file as a PDF — free

More than this page: up to 10 years of Douglas’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Douglas Hirsch compensation by year

GoodRx Summary Compensation Table · all 5 fiscal years held
In US dollars, as GoodRx reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022FY2023
Salary$500,000$500,000$500,000$500,000$500,000
Bonus$0$785$0$0$0
Stock awards$0$266,662,480$0$0$0
Option awards$0$0$0$0$0
Non-equity incentive$608,831$480,000$357,176$0$269,120
Pension and deferred compensation$0$0$0$0$0
All other$16,400$6,921$21,928$7,290$15,736
Total$1,125,231$267,650,186$879,104$507,290$784,856

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: GoodRx Holdings, Inc. DEF 14A filed April 25, 2024, accession 0001809519-24-000062, and prior-year filings. Open the filing on EDGAR.

How this page was built: the GoodRx Holdings, Inc. filed document, accession 0001809519-24-000062. Every figure is read from that document and cited to the page and table it appears in. Filed April 25, 2024.

$1.1M
$267.7M
$879K
$507K
$785K
FY19
FY20
FY21
FY22
FY23
SalaryBonusNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU769,784$5,157,553—

Per the Outstanding Equity Awards at Fiscal Year-End table in GoodRx Holdings, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments GoodRx discloses, by trigger · FY2023
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Death$416,667$1,719,187$29,659$2,165,513
Disability$416,667$1,719,187$29,659$2,165,513
Involuntary termination without cause$416,667$5,157,553$29,659$5,603,879
Resignation for good reason, no change in control$416,667$5,157,553$29,659$5,603,879
Change in control and involuntary termination$416,667$5,157,553$29,659$5,603,879
Change in control, no termination—$5,157,553$0$5,157,553

Per the Potential Payments Upon Termination or Change in Control table in GoodRx Holdings, Inc.'s FY2023 proxy. Estimates as the company printed them; a dash means it printed no figure.

GoodRx’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Scott WagnerFormer Interim Chief Executive Officer$10,144,526
Bansi NagjiFormer President, Healthcare$4,913,437
Romin NabieyChief Accounting Officer$2,583,887
Karsten VoermannFormer Chief Financial Officer$902,242
Trevor BezdekCo-Chairman of the Board$811,528
Douglas Hirsch · this pageChief Mission Officer$784,856

Board service

GoodRx board · FY2021–FY2025
Director compensation in US dollars, as GoodRx reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$30,000$224,777$0$0$254,777
FY2024$5,440$510,214$0$0$515,654
FY2022$0$0$0$0—
FY2021—————

Each year as the company reported it in GoodRx's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: GoodRx pays directors a $30,000 cash retainer and $230,000 in RSUs. As stated in GoodRx's FY2025 proxy.

The full GoodRx compensation record

free company brief

This page is one person within GoodRx's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the GoodRx proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are GoodRx's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Douglas Hirsch's compensation dossier · One-time report. No refunds.